Formulation
AssigneeAstra Aktiebolag
InventorsHans Nilsson, Gordon Santesson
Life of this patent
Estimating the term…
Abstract
A new metered unit dose comprising 40 μg or less of budesonide is disclosed as well as a formulation thereof and the use thereof for the treatment of conditions in the nose.
Claims29
A unit dose of a therapeutic composition comprising about 32 μg budesonide, wherein the budesonide
- (a) is in the form of finely divided particles, at least 90% of which have a mass equivalent sphere diameter of less than 20 μm, and
- (b) is suspended in an aqueous medium, wherein the pH is between 3.5 and 5.0,
- said composition being suitable for administration to a mammal in a single dose, wherein the composition includes no more than about 32 μg budesonide.
A therapeutic method of treating or preventing seasonal allergic rhinitis, perennial allergic rhinitis, non-allergic rhinitis, nasal polyps, chronic sinusitis, or recurrent sinusitis, the method comprising administering into a nostril of a mammal in need thereof a metered unit dose of finely divided budesonide particles, at least 90% having a mass equivalent sphere diameter of less than 20 μm, the particles being suspended in an aqueous medium, wherein said metered unit dose consists of about 32 μg budesonide and one or more ingredients other than budesonide.
A unit dose of a therapeutic composition, the active ingredient of which consists of about 32 μg budesonide formulated as finely divided particles, at least 90% of which have a mass equivalent sphere diameter of less than 20 μm, suspended in an aqueous medium, wherein the pH is between 3.5 and 5.0, said composition being suitable for administration to a mammal in a single dose.
Dependencies are inferred from the claim text.